CDIO
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Cardio Diagnostics Holdings, Inc. (CDIO) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-). The rating has held at C- for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C (2.2) | D (1.2) | D- (1.1) | C (2.5) | C+ (2.6) | C- (1.9) |
| 2026-11-04 | C (2.4) | D- (1.1) | D- (1.1) | C+ (2.8) | C+ (2.7) | C- (2.0) |
| 2026-10-28 | C (2.4) | D- (1.1) | D- (1.1) | C+ (2.8) | C+ (2.7) | C- (2.0) |
| 2026-10-21 | C (2.4) | D- (1.1) | D- (1.1) | C+ (2.6) | C+ (2.6) | C- (2.0) |
| 2026-10-14 | C (2.4) | D- (1.1) | D- (1.1) | C+ (2.7) | C+ (2.6) | C- (2.0) |